Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Highlights Innovations in Scalable, High-Throughput Transfection for Cell-Based Assays & Protein Production at the SBS Annual Meeting in Orlando, FL, Booth #812
March 28, 2011
MaxCyte, CCS Cell Culture Service, and Other Current Users Present Data Demonstrating Unmatched Cell Compatibility and Application Diversity
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is hosting a series of events at the 17th Annual Society for Biomolecular Sciences (SBS) Conference & Exhibition to be held March 27 - March 31, 2011, in Orlando, FL. MaxCyte will present scientific posters, conduct a tutorial, and schedule one-on-one discussions in Booth #812 to demonstrate how the MaxCyte® STX™ Scalable Transfection System can improve the physiological relevance and quality of cellular screening campaigns and can increase the efficiency and yield of protein production.
At the conference, MaxCyte will conduct a tutorial entitled, "Case Studies for the High Throughput Transfection of Functional Targets Using the MaxCyte® STX™ Scalable Transfection System," on Tuesday, March 29th, at 12:30PM in the Sarasota Room of the Gaylord Palms Convention Center. In this tutorial, Dr. Oliver Klotzsche, Managing Director of CCS Cell Culture Services GmbH, will present case studies demonstrating the simplicity and scalability of the MaxCyte® STX™ for producing assay-ready cells. In addition, Dr. James Brady, Director of Technical Applications at MaxCyte, will present data demonstrating the broad cell type compatibility of the MaxCyte® STX™, including stem cells, primary cells, insect cells, and other difficult-to-transfect cell lines, along with the performance of these transfected cells in downstream applications for cell-based screening and protein production.
MaxCyte will also present two scientific posters entitled, "High Throughput Transfection of Stem Cells, Primary Cells and Difficult-to-Transfect Cell Lines: Jurkat, CHO, Human Skeletal Muscle Cells & Primary Neuronal Cell Transfection using a Scalable, Electroporation-Based Technology (poster #W592)" and "Rapid and Scalable Transient Transfection Technology for High Titer Protein Production in HEK, CHO and Other Cell Types (poster #593)." MaxCyte scientists will be available at these posters on Wednesday, March 30, 2011, from 12:00pm to 1:30 PM to discuss these data.
Throughout the conference, the MaxCyte STX Scalable Transfection System will be on display and MaxCyte scientists and current scientific users will be available at Booth 812 to provide details about the latest use of transfected cells in protein production and functional, cell-based screening, including second messenger regulation, calcium flux, and automated electrophysiology assays.
"We believe this conference will strongly support the value of MaxCyte technology, with current users presenting their own transient transfection data, including cell usage in highly relevant functional assays," says Douglas Doerfler, President and CEO of MaxCyte. "MaxCyte is delighted to have such an exciting and diverse program for SBS which highlights the flexibility and scalability of the MaxCyte STX."
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed the MaxCyte® STX™ Scalable Transfection System, an ideal system for use in drug discovery research and screening as well as protein production environments. The MaxCyte STX provides for the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for protein production and for cell-based assays for ion channels, GPCRs, and other targets with comparable results and Seamless Scalability™ from the bench to HTS scale.